300422 Guangxi Bossco Environmental Protection Technology (A)

DGAP-News: Royalty Pharma Acquires Partial Royalty Interest on Prevymis(TM) (Letermovir) from AiCuris Anti-infective Cures GmbH

DGAP-News: AiCuris Anti-infective Cures GmbH / Key word(s): Agreement
Royalty Pharma Acquires Partial Royalty Interest on Prevymis(TM) (Letermovir) from AiCuris Anti-infective Cures GmbH

09.06.2020 / 14:00
The issuer is solely responsible for the content of this announcement.


Royalty Pharma Acquires Partial Royalty Interest on Prevymis(TM) (Letermovir) from AiCuris Anti-infective Cures GmbH


New York, NY, U.S. and Wuppertal, Germany, June 9, 2020 - Royalty Pharma and AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced today that they have entered into an agreement whereby Royalty Pharma has acquired a partial royalty interest on Prevymis(TM) (letermovir) from AiCuris for a one-time-payment of $220 million. Prevymis is licensed by MSD, the tradename of Merck & Co. Inc., Kenilworth, N.J., USA.

The product was approved by the U.S. Food & Drug Administration (FDA) in 2017 and by the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in 2018 for prophylaxis (prevention) of CMV infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) who are at high risk for CMV reactivation. CMV infection is a complication in these patients, and early CMV reactivation after transplant is associated with increased mortality.

"The agreement with Royalty Pharma reflects the major medical need for innovative anti-infective drugs and their commercial potential, and enables us to further advance our proprietary pipeline of novel treatments against infectious diseases without losing the possibility to participate on future revenues from Prevymis," said Dr. Holger Zimmermann, CEO of AiCuris Anti-infective Cures GmbH.

"We are excited to add a royalty interest in this important therapy to our portfolio," said Pablo Legorreta, Founder and CEO of Royalty Pharma.


Media and Investor Inquiries:

Royalty Pharma
George Grofik

+1 (212) 883-2299
AiCuris Anti-infective Cures GmbH
Katja Woestenhemke

0
 

About Royalty Pharma

Founded in 1996, Royalty Pharma is the industry leader in acquiring pharmaceutical royalties. Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors). The company's portfolio includes royalty interests in over 45 approved products including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta. Royalty Pharma is also a leading investor in pre-approval royalties, having since 2011 invested over $5.6 billion in royalties on pre-approval products and committed over $1.2 billion to direct R&D funding in exchange for royalties. For more information, visit


About AiCuris Anti-infective Cures GmbH

AiCuris was founded in 2006 as a spin-off from Bayer and focuses on the discovery and development of drugs targeting infectious diseases. SANTO Holding is the Company's majority investor. PREVYMIS(R) (Letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor acting via a novel mechanism of action, was licensed to MSD in 2012 and is approved in the EU, the USA, Japan and other parts of the world for use in bone marrow transplants for the prevention of HCMV infections in adults who receive an allogeneic hematopoietic stem cell transplant. The Company is developing drugs for the treatment of viruses such as human CMV, herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses. In the field of antibacterials, AiCuris seeks to develop innovative treatment options for life-threatening, multidrug-resistant, hospital-treated pathogens.

In 2018 Prof. Dr. Helga Rübsamen-Schaeff, Founding CEO, and Dr. Holger Zimmermann, CEO of AiCuris, were awarded the German Future Prize 2018 (German President's Award for Innovation in Science and Technology) for the development of Letermovir and their project, "Protection in the Absence of the Immune System - a Life-Saving Innovation against Dangerous Viruses" (original title: "Schutz bei fehlendem Immunsystem - die lebensrettende Innovation gegen gefährliche Viren").

For more information, please visit .
Follow us on

.[1] Prevymis is a trademark of MSD Sharp & Dohme GmbH.



09.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


1065933  09.06.2020 

fncls.ssp?fn=show_t_gif&application_id=1065933&application_name=news&site_id=research_pool
EN
09/06/2020

Underlying

300422Guangxi Bossco Environmental Protection Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Guangxi Bossco Environmental Protection Technology (A)

 PRESS RELEASE

Sunrise récompensée une nouvelle fois pour le meilleur service clients

Sunrise UPC GmbH / Mot-clé(s) : Autres Sunrise récompensée une nouvelle fois pour le meilleur service clients 31.08.2022 / 10:00 CET/CEST Sunrise remporte le test connect de la hotline du réseau fixe 2022. Sunrise établit à plusieurs reprises de nouvelles références en Suisse et dans la région DACH: Meilleur service clients pour le réseau fixe et haut débit (connect numéro 10/2022) Meilleur service clients pour la téléphonie mobile (connect numéro 5/2022) C’est le seul opérateur à remporter le test dans les deux domaines (téléphonie mobile, réseau fixe et haut débit)...

 PRESS RELEASE

Sunrise premiata di nuovo per il miglior servizio di assistenza client...

Sunrise UPC GmbH / Parola (s): Altro Sunrise premiata di nuovo per il miglior servizio di assistenza clienti 31.08.2022 / 10:00 CET/CEST Sunrise vince il test di connect 2022 dedicato al numero di assistenza per la rete fissa. Sunrise definisce nuovi standard in Svizzera e nella regione D-A-CH in diversi ambiti: miglior servizio di assistenza clienti per la rete fissa e la banda larga (connect numero 10/2022); miglior servizio di assistenza clienti per la telefonia mobile (connect numero 5/2022); unico operatore a vincere il test in entrambi i settore (telefonia mobi...

 PRESS RELEASE

Sunrise erneut für besten Kundendienst ausgezeichnet

Sunrise UPC GmbH / Schlagwort(e): Sonstiges Sunrise erneut für besten Kundendienst ausgezeichnet 31.08.2022 / 10:00 CET/CEST Sunrise gewinnt den connect Festnetz-Hotline-Test 2022. Sunrise setzt in der Schweiz und der DACH-Region gleich mehrfach neue Massstäbe: Bester Kundendienst für Festnetz und Breitband (connect Heft 10/2022) Bester Kundendienst für Mobilfunk (connect Heft 5/2022) Einziger Anbieter mit Testsieg in beiden Bereichen (Mobilfunk, Festnetz und Breitband) mit jeweils höchster Punktzahl über die 3 Länder hinweg «Schnelle Problemanalyse gepaart mit hoh...

 PRESS RELEASE

Sunrise wins award for best customer service once again

Sunrise UPC GmbH / Key word(s): Miscellaneous Sunrise wins award for best customer service once again 31.08.2022 / 10:00 CET/CEST Sunrise wins connect magazine’s landline hotline test 2022. Sunrise sets multiple new standards in Switzerland and the DACH region: Best customer service for landline and broadband (connect issue 10/2022) Best customer service for mobile (connect issue 5/2022) The only provider to win tests in both areas (mobile and landline/broadband) with the highest scores across the three countries. According to connect magazine, «rapid analysis of ...

 PRESS RELEASE

OPPO Explores New Technology Breakthroughs with Developers and Partner...

Oppo OPPO Explores New Technology Breakthroughs with Developers and Partners at OPPO Developer Conference 2022 31-Aug-2022 / 07:25 CET/CEST  OPPO Explores New Technology Breakthroughs with Developers and Partners at OPPO Developer Conference 2022   SHENZHEN, CHINA - - 31 August 2022 - OPPO kicked off its 2022 OPPO Developer Conference (ODC 2022) today, unveiling its Pantanal cross-platform smart system, OPPO Carlink solution for enhanced smartphone-car integration, and the OPPO Sense® health algorithm along with an RMB 2 billion plan to support developers and creators working with...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch